Diagnosed with SMM, SPB, or MGUS?
Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
- You are here:
- Home »
- Blog »
- Pre-Myeloma »
- Plasmacytoma vs. Multiple Myeloma
Plasmacytoma vs. Multiple Myeloma
What is the difference between a Single Plasmacytoma of bone (SBP) and Multiple Myeloma(MM)?
A diagnosis of a single plasmacytoma of bone (SPB), smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS) are all diagnostic terms of “PRE-Multiple Myeloma.” That is to say, a diagnosis of any of these is not cancer but a diagnosis of a blood disorder. While these diagnoses may increase the risk of and/or lead to full-blown multiple myeloma, an incurable blood cancer, they are NOT cancer.
A diagnosis of full multiple myeloma, stages 1,2 or 3 is cancer. In short, the difference between a single plasmacytoma and multiple myeloma is one vs. many lytic lesions.
I was originally diagnosed with a single plasmacytoma of bone. I underwent local surgery to remove the monoclonal proteins in my neck (the lytic lesion) and then underwent local radiation to zap any MM cells that the surgeon may have missed.
My oncologist told me that there was a small chance that my SBP would not become MM and that there was nothing I could do but watch and wait.
I wish I knew then what I know now.
The question on the minds of those diagnosed with pre-myeloma often is “what, if anything, can be done to remain pre-MM? Is there anything that can be done that is not chemotherapy aka toxic? I believe there is. I live an evidence-based, anti-MM lifestyle based on nutrition, supplementation, bone health and mind-body therapies that has kept me in complete remission since 1999. Curcumin, for example, has been show to reduce your risk of progressing to full-blown MM.
To learn more about the evidence-based, anti-MM lifestyle I’m talking about, please watch the short video below:
I am both a long-term MM survivor and MM cancer coach.
If you do not want to “watch and wait” to see if your pre-MM progresses to Multiple Myeloma scroll down the page, post a question or a comment and I will reply to you ASAP.
Please consider:
- evidence-based, non-toxic, cytotoxic/apoptotic supplements,
- anti-MM nutrition,
- evidence-based mind-body therapies,
- detoxification therapies,
- evidence-based, non-toxic bone health therapies
- information about cannabis as MM therapy
- To Learn More About Solitary Bone Plasmacytoma- click now
- To Learn More about plasma cells and autologous stem cell transplantation- click now
Thank you,
David Emerson
- Myeloma Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Recommended Reading-
- Monoclonal Gammopathy of Undetermined Significance (MGUS) Nerve Pain
- Smoldering Multiple Myeloma (SMM) Facts and Statistics
- MGUS Screening?
- MGUS-“Comparatively Lower Life Expectancy?”
What to know about solitary plasmacytoma
“Solitary plasmacytoma refers to a single abnormal mass, or tumor, that consists of plasma cells, known as a plasmacytomaTrusted Source. Plasma cells are a type of white blood cell that has an important role in immunity.
A plasmacytomaTrusted Source may progress into multiple myeloma. This is another type of cancer that affects white blood cells. Some people may also describe solitary plasmacytoma as a subdivision of multiple myeloma.
The name solitary plasmacytoma derivesTrusted Source from the fact that instead of multiple tumors in different locations, like in multiple myeloma, there is only one tumor. Many doctors believe that solitary plasmacytoma is an early, isolated form of multiple myeloma. As many people with solitary plasmacytoma may develop multiple myeloma, it is important to watch closely for signs of multiple myeloma…”
Solitary plasmacytoma of bone and asymptomatic multiple myeloma
“Most patients with multiple myeloma (MM) present with symptoms, have evidence of generalized disease, and require chemotherapy promptly to reduce the malignant clone. Some patients present with a local symptom from a single plasmacytoma but no myeloma elsewhere. Such patients usually become free of symptoms after local radiotherapy.
In patients with MM without symptoms, the diagnosis is made on the basis of screening laboratory tests. In patients with either solitary plasmacytoma of bone or asymptomatic MM, systemic treatment should be deferred until there is evidence of disease progression…
Future directions
In most patients with SPB and residual myeloma protein or with asymptomatic myeloma and increased risk factors, overt MM develops within 3 years…
In view of the projected long survival of most patients, more intensive therapy supported by autologous stem cell transplantation should be deferred until MM becomes more evident, when the potential clinical benefit clearly outweighs the risks.
The prophylactic role of bisphosphonates in maintaining bone mineralization appears less clear, since no controlled studies have been conducted in patients without lytic bone lesions or in very early phases of disease. One can envision randomized multicenter trials in selected patients with asymptomatic myeloma and reduced bone density…”
Curcumin
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.[1]“
Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers.
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”